Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 9, 2009

Medarex Taps Lonza for Biomanufacturing

  • Medarex obtained an option to work with Lonza as a provider of manufacturing services to support development and commercialization of its pipeline. Medarex is developing protein-based treatments and antibody drug conjugates (ADCs).

    Lonza notes that this agreement marks the firm’s growing business model from a short-term product-by-product development and manufacturing arrangement toward more strategic long-term collaborations on a pipeline of products.

    Under the terms of the deal, Lonza may provide process-development services for certain programs. The firm may also reserve manufacturing capacity for antibody and ADC programs at its facilities around the world. Lonza reportedly has the ability to produce ADCs in milligram to multiple kilogram quantities for both clinical and commercial supply.

    Medarex’ pipeline is focused on oncology and immunology and comprises 10 antibody programs in clinical development. Its lead candidate is ipilimumab, which is being developed with Bristol-Myers Squibb in Phase III for various cancers.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »